piroxicam
Trade name: feldene
Approved
Apr 6, 1982
Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). It was originally brought to market by Pfizer under the tradename Feldene in 1980, became generic in 1992, and is marketed worldwide under many brandnames. Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis. The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets. Piroxicam is used for treatment of osteoarthritis and rheumatoid arthritis. — NCATS
Clinical trial activity
27 trials · 46 clinical orgs · 19 marketing orgs
Earliest trial started Jan 1, 2003 (NCT00649415)
Timeline
1990s
- May 29, 1992
Boston Scientific Corporation — Marketing Organization
- Jul 31, 1992
Mylan — Marketing Organization
- Aug 28, 1992
Teva — Marketing Organization
- Mar 12, 1993
Sun Pharmaceuticals — Marketing Organization
- Mar 12, 1993
Mutual Pharmaceutical — Marketing Organization
- Jun 15, 1993
Nostrum Laboratories — Marketing Organization
- Sep 29, 1995
Watson Pharmaceuticals — Marketing Organization
- Jul 8, 1997
Egis — Marketing Organization
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2016
Earliest Phase 3 Sponsor(trial)
- Sep 9, 2016
Flamingo Pharmaceuticals — Marketing Organization
- Apr 13, 2017
Unichem — Marketing Organization
- Jun 20, 2017
Pharmaceutics International, Inc. — Marketing Organization
- Aug 11, 2017
Hikma — Marketing Organization
- Dec 29, 2017
Micro Labs Ltd India — Marketing Organization
- Jan 26, 2018
Strides Pharma Science — Marketing Organization
- Feb 21, 2018
Esteve Labs — Marketing Organization
- Jul 17, 2018
Cadila Healthcare — Marketing Organization
- Jul 17, 2018
Zydus Discovery DMCC — Marketing Organization
Indications
Approved for
Studied for
- Acute Pain · Phase 2/Phase 3
- Anesthesia · Phase 2/Phase 3
- Anorexia · Phase 2
- Cachexia · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Contraception · Phase 3
- Contraception, Postcoital · Phase 2/Phase 3
- Cytochrome P-450 CYP2C19 · Phase 4
- Dentin Sensitivity · Phase 3
- Dysmenorrhea · Phase 4
- General Surgery · Phase 4
- Hypertension · Phase 4
- Osteoarthritis, Knee · Phase 2
- Pain · Phase 4
- Postoperative Pain · Phase 2/Phase 3
- Pulpitis · Phase 4
- Renal Colic · Phase 2
- Tennis Elbow · Phase 2/Phase 3
- Tooth Abnormalities · Phase 4
- Toothache · Phase 3
- Traumatology · Phase 3
- Weight Loss · Phase 2
- Wound Infection · Phase 2/Phase 3
Mechanism of action
- CyclooxygenaseINHIBITOR
Cyclooxygenase inhibitor
Approval history
- approvedApr 6, 1982
Chemistry & pharmacology
SMILES
CN1C(C(=O)NC2=CC=CC=N2)=C(O)C3=CC=CC=C3S1(=O)=O- Mol. weight
- 331.346 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPiroxicam ↗
- NCATS13T4O6VMAM ↗
- ChEMBLCHEMBL527 ↗
- ChEMBLCHEMBL2108444 ↗
Also known as
- 4-hydroxy-2-methyl-n-(2-pyridyl)-2h-1,2-benzothiazin-3-caboxyamid-1,1-dioxid
- 4-hydroxy-2-methyl-n-(2-pyridyl)-2h-1,2-benzothiazin-3-caboxyamid-1,1-dioxid
- betamarc
- brexicam
- brexidol
- brexidol
- brexidol
- brexin
- cicladol
- cp16171
- cp-16171
- cp-16171
- cp-16171
- feldene
- feldene
- feldene
- feldene
- feldene
- feldene
- feldene 20
- feldene p
- flamatrol
- kentene
- larapam
- larapam
- piroflam 10
- piroflam 20
- piroxicam
- piroxicam
- piroxicam
- piroxicam
- piroxicam
- piroxicam
- piroxicam
- piroxicam
- piroxicam
- piroxicam beta-cyclodextrin
- piroxicam-beta-cyclodextrin
- piroxicam-beta-cyclodextrin complex
- piroxicam betadex
- piroxicam betadex
- piroxicam betadex
- piroxicam betadex
- piroxicam betadex
- piroxicamum
- piroxicamum
- pirozip 10
- pirozip 20
- pyroxycam
- pyroxycam
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07281807 | Phase 4 | Jan 1, 2026 | Shaheed Zulfiqar Ali Bhutto Medical University |
| NCT06727734 | Phase 3 | Dec 31, 2024 | The Family Planning Association of Hong Kong, The University of Hong Kong |
| NCT06404177 | Phase 3 | Jul 15, 2023 | Hôpital Universitaire Sahloul |
| NCT05722782 | Phase 2 | Jul 1, 2023 | University of Monastir |
| NCT05488925 | Phase 4 | Jun 21, 2021 | Baqai Medical University |
| NCT05104931 | Phase 1 | Dec 2, 2020 | Nanoform Finland Plc, Quotient |
| NCT06943092 | N/A | Jan 11, 2020 | Federal Teaching Hospital Abakaliki |
| NCT04201249 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2019 | Hospital de Santa Maria, Portugal |
| NCT04062591 | Early Phase 1 (Phase 1) | Aug 16, 2019 | Ain Shams University |
| NCT03998826 | N/A | Jul 1, 2019 | Cairo University |
| NCT05054023 | Phase 2/Phase 3 (Phase 3) | Jan 21, 2019 | University of Monastir |
| NCT03745105 | N/A | Dec 25, 2018 | Cairo University |
| NCT03612323 | Early Phase 1 (Phase 1) | Nov 30, 2018 | Cairo University |
| NCT03614494 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2018 | The Family Planning Association of Hong Kong, The University of Hong Kong |
| NCT03881319 | N/A | Jun 1, 2018 | Taipei Medical University |
| NCT04124822 | Phase 2/Phase 3 (Phase 3) | May 30, 2018 | Dow University of Health Sciences |
| NCT03153657 | Phase 3 | Dec 13, 2016 | Universidade Federal de Sergipe |
| NCT03626753 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2015 | University of Monastir |
| NCT02382653 | N/A | Dec 1, 2014 | Tanta University |
| NCT02304783 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2014 | University of Monastir |
Organizations
Research & Development (46)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Monastir | Academic/Hospital | 4 | 4 | 2 | 2014 |
| Cairo University | Academic/Hospital | 3 | 3 | 2 | 2018 |
| The University of Hong Kong | Academic/Hospital | 3 | 2 | 2 | 2007 |
| Taipei Medical University | Academic/Hospital | 2 | 1 | 2 | 2007 |
| The Family Planning Association of Hong Kong | Academic/Hospital | 2 | 0 | 1 | 2018 |
| Ain Shams University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Anaborex | For profit | 1 | 1 | 1 | 2007 |
| Ardabil University of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Baqai Medical University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Bayer | For profit | 1 | 1 | 1 | 2011 |
| Cathay General Hospital | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Catholic University of Korea | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Chang Gung University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Changhua Christian Hospital | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Chimei Medical Center | Academic/Hospital | 1 | 0 | 1 | 2007 |
| China Medical University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Chung Shan Medical University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| City University of Hong Kong | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Dharmais Cancer Hospital | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Dow University of Health Sciences | Academic/Hospital | 1 | 1 | 1 | 2018 |
Marketing (25)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Boston Scientific Corporation | For profit | MKTG | May 29, 1992 |
| Cadila Healthcare | For profit | MKTG | Jul 17, 2018 |
| Cycle Pharmaceuticals Ltd. | For profit | MKTG | — |
| Egis | For profit | MKTG | Jul 8, 1997 |
| Esteve Labs | For profit | MKTG | Feb 21, 2018 |
| Esteve Labs | For profit | SYN | Jun 20, 2017 |
| Flamingo Pharmaceuticals | For profit | MKTG | Sep 9, 2016 |
| Hikma | For profit | MKTG | Aug 11, 2017 |
| Hikma | For profit | SYN | Aug 11, 2017 |
| Micro Labs Ltd India | For profit | MKTG | Dec 29, 2017 |
| Mutual Pharmaceutical | For profit | MKTG | Mar 12, 1993 |
| Mylan | For profit | MKTG | Jul 31, 1992 |
| Mylan | For profit | SYN | Jun 15, 1993 |
| Nostrum Laboratories | For profit | MKTG | Jun 15, 1993 |
| Pfizer | For profit | NDA | Apr 6, 1982 |
| Pharmaceutics International, Inc. | For profit | MKTG | Jun 20, 2017 |
| Strides Pharma Science | For profit | MKTG | Jan 26, 2018 |
| Sun Pharmaceuticals | For profit | MKTG | Mar 12, 1993 |
| Teva | For profit | SYN | Jun 3, 1996 |
| Teva | For profit | SYN | Dec 11, 1992 |
| Teva | For profit | MKTG | Aug 28, 1992 |
| Unichem | For profit | MKTG | Apr 13, 2017 |
| Unichem | For profit | SYN | Apr 13, 2017 |
| Watson Pharmaceuticals | For profit | MKTG | Sep 29, 1995 |
| Zydus Discovery DMCC | For profit | MKTG | Jul 17, 2018 |